Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Tenax Therapeutics Inc (TENX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Tenax Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.8400 -0.0200    -0.52%
03/05 - Closed. Currency in USD ( Disclaimer )
After Hours
3.7100
-0.1300
-3.3854%
19:59:34 - Real-time Data
  • Volume: 11,652
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 3.7800 - 3.8489
Type:  Equity
Market:  United States
Tenax Therapeutics 3.8400 -0.0200 -0.52%

Tenax Therapeutics Inc Company Profile

 
Get an in-depth profile of Tenax Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Contact Information

Address 101 Glen Lennox Drive Suite 300
Chapel Hill, 27517
United States
Phone (919) 855-2100
Fax -

Top Executives

Name Age Since Title
Daniel Burkhoff - 2018 Member of PH-Left Heart Disease Scientific Advisory Board
Sanjiv Shah - 2018 Member of PH-Left Heart Disease Scientific Advisory Board
Bradley Maron - - Member of PAH Scientific Advisory Board
Christopher T. Giordano 49 2021 CEO, President & Director
Anna R. Hemnes - - Member of PAH Scientific Advisory Board
Declan Doogan 72 2021 Independent Director
Gerald T. Proehl 65 2014 Independent Chairman
Barry Borlaug - 2020 Member of PH-Left Heart Disease Scientific Advisory Board
Stuart Rich 74 2018 Chief Medical Officer & Director
Robert P. Frantz - - Member of PAH Scientific Advisory Board
Michael Harvey Davidson 68 2021 Independent Director
Robyn M. Hunter 62 2022 Independent Director
June S. Almenoff 67 2021 Independent Director
Javed Butler - 2023 Member of PH-Left Heart Disease Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TENX Comments

Write your thoughts about Tenax Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email